Advances in Bevacizumab Therapy for Non-small Cell Lung Cancer with Brain Metastases
10.3779/j.issn.1009-3419.2016.08.05
- VernacularTitle:贝伐珠单抗治疗非小细胞肺癌脑转移的研究进展
- Author:
QU LIYAN
1
;
GENG RUI
;
SONG XIA
Author Information
1. 山西医科大学附属山西省肿瘤医院呼吸科
- Keywords:
Lung neoplasms;
Brain metastases;
Bevacizumab
- From:
Chinese Journal of Lung Cancer
2016;19(8):515-518
- CountryChina
- Language:Chinese
-
Abstract:
Brain metastases are frequently encountered in patients with non-small cell lung cancer (NSCLC) and are a signiifcant cause of morbidity and mortality. Antiangiogenesis therapy plays a major role in the management of brain metastases in lung cancer. Bevacizumab have become the novel method for the treatment of lung cancer with brain metastases beyond the whole brain radiation therapy, stereotactic radiosurgery and chemotherapy. Recently, more and more studies and trials laid emphasis on the bevacizumab for NSCLC with brain metastases treatment. hTe key point is the effcacy and safety. In this review, bevacizumab therapy of NSCLC with brain metastases were summarized.